Oceanpine Capital is a professional investment management firm dedicated to long-term investment with a focus on value creation.
Business Model:
Revenue: $0
Employees: 0-0
Address: 1 Garden Road
City: Central
State: hong kong special administrative region
Zip: 999077
Country: CN
Oceanpine Capital is a professional investment management firm dedicated to long-term investment with a focus on value creation. We provide long-term capital and professional value-added services to high-growth enterprises and start-up companies. Oceanpine Capital is headquartered in Hong Kong with offices in Beijing and San Francisco. We focus on investment opportunities in the TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. We mainly invest in private companies with rapid growth, but also look at some opportunities in public companies. Our professional team consists of entrepreneurs, investment professionals, investment bankers and company executives with proven track records. As a team, we stand out in terms of providing strategic resources support and professional value-added services to our investee companies along with our capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2022 | Lianshu Technology | Angel Round | 0 |
2/2022 | Clounix | Series A | 0 |
3/2021 | Immune-Onc Therapeutics | Series B | 0 |
10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
5/2020 | Enflame | Series B | 98.8M |
6/2019 | Enflame | Series A | 0 |
3/2021 | JuLive.com | Series C | 61.6M |
3/2022 | Shenzhen Shifeng | Series A | 0 |
5/2021 | Weilong Foods | Series A | 558M |
6/2021 | Tongshu Gene | Series C | 78.1M |
4/2021 | TechnoDerma Medicines | Series A | - |
9/2020 | XtalPi | Series C | 318.8M |
12/2021 | OrthoGuard | Series A | - |
2/2019 | Horizon Robotics | Series B | 0 |
9/2021 | MingMed | Series A | 0 |
11/2022 | SIRUI | Venture Round | - |
8/2020 | Sinovent | Series C | 144.7M |
8/2021 | Svolt Energy Technology Co., Ltd. | Series B | 0 |
2/2021 | Clover Biopharmaceuticals | Series C | 230M |
7/2018 | Tiger Brokers | Series C | 80M |
12/2021 | Chipone Technology | Series E | 0 |
9/2022 | Qinghai Lihao | Series B | 306.5M |
8/2022 | Enflame | Series C | - |
8/2020 | HireEZ | Series B | 13M |
8/2020 | Triumvira Immunologics | Series A | 0 |
12/2021 | Yuchuang Semiconductor | Series A | 15.7M |
8/2018 | 51zhaoyou.com | Series C | 150M |
9/2020 | Creative Biosciences | Series C | 87.9M |
10/2019 | Ansun BioPharma | Series B | 100M |
2/2021 | Teon Therapeutics | Series A | 0 |
5/2022 | Aqronos | Series A | - |
3/2020 | Apexigen | Series C | 65M |
1/2023 | Kuixin Technology | Series A | 14.8M |
5/2018 | Ansun BioPharma | Series A | 85M |
2/2021 | Yisheng Biopharma | Series B | 0 |
5/2022 | Aqronos | Series A | - |
3/2022 | Shenzhen Shifeng | Series A | 0 |
2/2022 | Clounix | Series A | 0 |
2/2022 | Lianshu Technology | Angel Round | 0 |
12/2021 | OrthoGuard | Series A | - |
12/2021 | Yuchuang Semiconductor | Series A | 0 |
12/2021 | Chipone Technology | Series E | 0 |
9/2021 | MingMed | Series A | 0 |
8/2021 | Svolt Energy Technology Co. | Series B | 0 |
6/2021 | Tongshu Gene | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|